Verastem paid its 4 named executives $5.2M in total in FY2025 (Dec). CEO Daniel Paterson was paid $2.3M of that.
Pay$100 in the stock at the end of FY21 → $31
Pay of each named executive
Daniel PatersonPresident and Chief Executive Officer
| FY2025 (Dec) | ||||||
| FY2024 (Dec) | ||||||
| FY2023 (Dec) | ||||||
| FY2022 (Dec) |
4 years
Matthew RosFormer Chief Operating Officer
| FY2025 (Dec) | ||||||
| FY2024 (Dec) |
2 years
Daniel CalkinsChief Financial Officer
| FY2025 (Dec) | ||||||
| FY2024 (Dec) | ||||||
| FY2023 (Dec) | ||||||
| FY2022 (Dec) |
4 years
Michael Kauffman, M.D., Ph.D.President of Development
| FY2025 (Dec) | ||||||
| FY2024 (Dec) |
2 years
CEO pay against the pay peers
In FY2025 (Dec), the median CEO pay of the 5 peers with pay on file was $5.1M. The CEO of Verastem was paid $2.3M, 54% below the median.
- 1Scholar Rock Holding
- 2Cogent Biosciences
- 3Compass Therapeutics
- 4Kura Oncology
- 5Olema Pharmaceuticals
- 6VerastemThis company
- 7Acrivon Therapeutics, Inc.Not disclosed
- 8Actinium Pharmaceuticals, Inc.Not disclosed
- 9Aura BiosciencesNot disclosed
- 10Cardiff OncologyNot disclosed
- 11CelcuityNot disclosed
- 12Cullinan Oncology, Inc.Not disclosed
- 13Leap Therapeutics, Inc.Not disclosed
- 14Lian BioNot disclosed
- 15MEI Pharma, Inc.Not disclosed
- 16Syros Pharmaceuticals, Inc.Not disclosed
- 17Terns Pharmaceuticals, Inc.Not disclosed
- 18iTeos Therapeutics, Inc.Not disclosed
Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.